about
Design of Phase II cancer trials evaluating survival probabilitiesStatistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trialsPhase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group.A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group studyExploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment.What inference for two-stage phase II trials?Phase II clinical trials in oncology: strengths and limitations of two-stage designs.A review of phase II trial designs for initial marker validation.Controlled multi-arm platform design using predictive probability.A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.Phase II trial design with Bayesian adaptive randomization and predictive probability.Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study.A multi-center, phase ii clinical trial of Padexol (paclitaxel) and cisplatin for patients suffering with advanced gastric cancer.Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial. [Corrected].Improved two-stage tests for stratified phase II cancer clinical trials.Optimal two-stage log-rank test for randomized phase II clinical trialsMethods for proper handling of overrunning and underrunning in phase II designs for oncology trials.Between-arm comparisons in randomized Phase II trialsBayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity.Phase II design with sequential testing of hypotheses within each stage.Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis.Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).Designs for randomized phase II clinical trials with two treatment arms.A Bayesian-frequentist two-stage single-arm phase II clinical trial design.Estimation of secondary endpoints in two-stage phase II oncology trials.A Phase II clinical trial of idarubicin administered to children with relapsed brain tumors.The efficacy and safety of Padexol (paclitaxel) and cisplatin for treating advanced non-small cell lung cancer.P-value calculation for multistage phase II cancer clinical trials.Optimal two-stage designs for single arm phase II cancer trials.Multinomial phase II cancer trials incorporating response and early progression.Methodology and Application of Adaptive and Sequential Approaches in Contemporary Clinical Trials
P2860
Q24802587-8992B176-FE93-4210-BE32-D0F8582CA36AQ26849875-402FEB99-C07F-4692-927C-D1BD68C5533AQ33381940-F06D3B73-FF74-44B8-90E5-2F2FB5D3BF82Q33390957-429F473D-F3C3-489B-9308-E9D4D33BEAD8Q33923067-F1900CA6-0B36-4F30-BFF0-663F9DAD6818Q34367748-48172DE9-C148-4CB4-9FCF-B6F0F688F4DBQ36508078-49091573-ACFD-4021-B89D-B036B00A55CEQ37188715-212549B9-4C23-449E-858E-DB53A1CB17E1Q37289826-5A6A5566-D0F9-44D3-8320-2A884FF3F8C2Q37310514-F7E77E35-4AFB-4886-AA75-DAB1A76F42AFQ37320508-48677AD1-C736-4128-AAFF-A6BBF203B476Q37368518-B285EFE7-220A-4248-8C0D-4936C7E846F8Q37449306-F9BFD897-BD39-47B6-AC09-98935F7ABA14Q37624187-2A86AB04-150A-4FB5-B823-150959628899Q37678121-4514FAD4-D148-43F9-8FC3-6E59B28C3A5CQ40815466-EFDB18A7-CE19-4B08-9096-75D823E417D8Q41203314-6DCFD8E6-06B6-4849-B383-DD19AC5EB069Q42012850-757A531B-F298-478F-B9C0-1B3BEB9482D3Q42655294-30FDC64D-47FC-47DD-93E0-E7252285F444Q43427263-88A0874E-D7E7-43CF-B2A5-86318262A576Q44029244-412055BD-C3E7-4823-8892-BDF559BF731CQ45927534-27521BAD-F89D-44CB-988B-077DE8AF0FEDQ46031432-500EA924-075B-48B4-8C2F-4C73E0760EBEQ46433182-59F08370-E5F6-4739-A2B4-CFC2FAAA5C3BQ47210436-FB440C39-4083-4B99-9045-4FFDF12FB07DQ48405212-FAF672F0-8CEF-440C-9C85-8BAD91519015Q50317333-40E5AA3B-892F-41FB-9076-15A312F07243Q51927567-7AFA6512-9CB8-4854-A06A-A9E4C553E2CAQ52035771-CA373565-5058-422D-87C7-FE4225CC532EQ52211232-AD1CC852-6843-40F9-A3A0-A913FFF8B0DCQ58910970-BEFFC72B-F7E6-4280-87C9-21EE0BAAB6E9
P2860
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh-hant
name
Designs for group sequential phase II clinical trials.
@en
Designs for group sequential phase II clinical trials.
@nl
type
label
Designs for group sequential phase II clinical trials.
@en
Designs for group sequential phase II clinical trials.
@nl
prefLabel
Designs for group sequential phase II clinical trials.
@en
Designs for group sequential phase II clinical trials.
@nl
P2093
P356
P1433
P1476
Designs for group sequential phase II clinical trials.
@en
P2093
P304
P356
10.2307/2531540
P407
P577
1987-12-01T00:00:00Z